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A population of patients with unexplained neurological symptoms from six major French university hospitals was
screened over a 28-month period for primary creatine disorder (PCD). Urine guanidinoacetate (GAA) and creatine:
creatinine ratios were measured in a cohort of 6,353 subjects to identify PCD patients and compile their clinical,
1H-MRS, biochemical and molecular data. Six GAMT [N-guanidinoacetatemethyltransferase (EC 2.1.1.2)] and 10
X-linked creatine transporter (SLC6A8) but no AGAT (GATM) [L-arginine/glycine amidinotransferase (EC 2.1.4.1)]
deficient patients were identified in this manner. Three additional affected sibs were further identified after familial
inquiry (1 brother with GAMT deficiency and 2 brothers with SLC6A8 deficiency in two different families). The
prevalence of PCD in this population was 0.25% (0.09% and 0.16% for GAMT and SLC6A8 deficiencies, respectively).
Seven new PCD-causing mutations were discovered (2 nonsense [c.577C > T and c.289C > T] and 1 splicing
[c.391 + 15G > T] mutations for the GAMT gene and, 2 missense [c.1208C > A and c.926C > A], 1 frameshift
[c.930delG] and 1 splicing [c.1393-1G > A] mutations for the SLC6A8 gene). No hot spot mutations were observed in
these genes, as all the mutations were distributed throughout the entire gene sequences and were essentially
patient/family specific. Approximately one fifth of the mutations of SLC6A8, but not GAMT, were attributed to
neo-mutation, germinal or somatic mosaicism events. The only SLC6A8-deficient female patient in our series
presented with the severe phenotype usually characterizing affected male patients, an observation in agreement
with recent evidence that is in support of the fact that this X-linked disorder might be more frequent than
expected in the female population with intellectual disability.* Correspondence: joseph.vamecq@inserm.fr
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Creatine is a physiological compound that was first iso-
lated by the French chemist Eugène Chevreul in the
1830s [1]. It is supplied to the body both via endogenous
biosynthesis and the diet [2-4]. Its name (the Greek
‘kreas’ means meat) originates from its abundance in
muscle in which its energetic role has previously been
documented [5-8]. Creatine can be phosphorylated by
creatine kinases, leading to the storage of a high-energy
phosphate bond of ATP in the form of phosphocreatine
[3]. Upon demand, and due to the reversible activity of
creatine kinases which can transform ADP back into
ATP, phosphocreatine can release the stored energy [3].
This creatine/phosphocreatine cycle represents a vital
reserve of energy in tissues with high energetic needs
such as muscles and the brain [3]. In recent years, the
physiological role of brain creatine has been extended to
include the modulatory control of neurotransmission
which, in addition to guanidinoacetate (GAA) toxicity,
has improved our understanding of brain function and
its severe impairment in disorders affecting creatine bio-
synthesis and transport [9-12].
The first step of creatine biosynthesis occurs essen-
tially but not exclusively in the kidney and involves
the transfer of an amidino group from arginine to glycine
by the enzyme L-arginine/glycine amidinotransferase
(AGAT) (EC 2.1.4.1) to form GAA and L-ornithine. Sub-
sequently, N-guanidinoacetatemethyltransferase (GAMT)
(EC 2.1.1.2) catalyzes the transfer of a methyl group from
S-adenosyl methionine (SAM) on GAA. This second step
occurs notably in the liver and leads to the formation of
creatine and S-adenosylhomocysteine (SAH) [3]. Once
synthesized, creatine may be released into the blood-
stream. It can be internalized by cells via a specific plasma
membrane Na+/Cl- dependent creatine transporter
(SLC6A8) and stored as phosphocreatine [3]. Finally,
about 1.7% of the creatine/phosphocreatine pool under-
goes spontaneous degradation each day forming creatinine
that is excreted in urine [3]. Urinary excretion of creatin-
ine is a function of body muscle mass and in practice is a
useful marker of kidney function. Little or no creatine is
taken up by the brain from the systemic bloodstream
because the blood brain barrier is practically imperme-
able to creatine. The brain must therefore secure most
of its requirements in creatine by endogenous synthesis
[10,11,13]. The crucial role of SLC6A8, which has been
reviewed recently [14], provides ground for understanding
how its deficiency results in a creatine collapse in brain.
Extracerebral and intracerebral routes for creatine sup-
plies concur and their respective contributions differ in
the immature (i.e. fetal and perinatal) and mature brain.
In the immature brain, the extracerebral supply is
favored due to a better efficacy of SLC6A8 in the blood–
brain barrier (BBB). This means that extraction ofcreatine from the blood is predominant over intracereb-
ral creatine biosynthesis which is physiologically limited
by low GAMT activity in the immature brain [14].
SLC6A8 deficiency affects the immature brain creatine
content through impairment of BBB uptake. In the ma-
ture brain, the contribution of BBB SLC6A8 becomes
physiologically lower and intracerebral biosynthesis
becomes the major pathway for the supply of brain cre-
atine [14]. SLC6A8 deficiency therefore affects the ma-
ture brain creatine content through impairment of
intracerebral creatine biosynthesis as a result of reduced
SLC6A8-driven transfer of GAA from brain GAA to
creatine-synthesizing cells. Differences existing between
the extracellular/intracellular routes for the brain creat-
ine supply explain why creatine supplementation is more
efficient in two other creatine disorders, AGAT and
GAMT deficiencies, when given at a presymptomatic
stage of the disease when BBB uptake of creatine is
physiologically optimal [14,15]. An illustrated account of
creatine biosynthesis and transport is provided in the
Additional file 1.
Primary creatine deficiency disorders (PCD) are a
new class of inborn errors of metabolism to which be-
long AGAT (OMIM 602360) and GAMT (OMIM
601240) deficiencies, both inherited as an autosomal re-
cessive trait, and SLC6A8 [CT1, CRTR] deficiency
(OMIM 300036), an X-linked disorder [10-12,16-20].
The three disorders share a relative reduction of brain
creatine and phosphocreatine levels [19], and accord-
ingly, the clinical presentation is predominated by
neurological signs [10-12,16-20]. However, these disor-
ders still remain under-diagnosed whether considered
together [16-20] or individually (AGAT [21-25], GAMT
[26,27] or CRTR [28-33] deficiency).
In this paper we present the results of a large retro-
spective study of urinary screening for PCD on 6,353
patients in whom the etiology of the underlying neuro-
logical disease was unknown at the time of urinary ana-
lysis of creatine and its metabolites.
Patients and methods
We retrospectively collected the metabolic results of
urinary screening for PCD (GAA and creatine:creatinine
ratios) from 6,353 patients with neurological disease of
unknown origin (4,426 male patients and 1,927 female
patients) hospitalized in six French university hospitals
(Angers, Lille, Lyon and Paris (Hôpital Necker Enfants
Malades, Hôpital Robert Debré and Hôpital Raymond
Poincaré)) over a period of 28 months. Data with regard
to GAA and creatine levels in plasma were also col-
lected when available. For all patients with an abnormal
result, a second sample was analyzed after a 24-hour
diet devoid of meat and fish according to the recom-
mendation of Arias et al. [34]. A patient was considered
Cheillan et al. Orphanet Journal of Rare Diseases 2012, 7:96 Page 3 of 10
http://www.ojrd.com/content/7/1/96“at risk of PCD” (AGAT, GAMT or SLC6A8 deficiency)
when the biochemical abnormality was confirmed on
this second sample. Subsequently a molecular study
and/or a functional test were performed to confirm the
diagnosis. For the genetic study, informed consent was
obtained from each patient or from their parents if pro-
bands were under 18. For patients with a confirmed
diagnosis of PCD, extensive clinical data were collected,
including familial, obstetrical and personal histories,
main symptoms having led to consult, the specialty of
the physician who requested metabolic investigations,
the patient’s age at diagnosis, clinical signs present at
diagnosis and results of 1H-MRS exploration. All
patients with other diagnosed conditions (in particular,
urea cycle disorders and remethylation defects) were
discarded from the study.Methods for metabolite measurements
Creatine and GAA levels were measured in urine and
plasma by tandem mass spectrometry (LC-MS/MS)
using stable isotopes as internal standards (13C2-GAA
and 2H3-creatine) according to a method described
previously [35]. Urinary creatinine was measured using
LC-MS/MS using a specific internal standard (2H3-
creatinine), except in two university hospitals in Paris
(Necker Enfants Malades and Robert Debré) where this
measurement was performed using the colorimetric Jaffé
method [36,37]. The control values and age groups used
for plasma and urine GAA and creatine concentrations
were those published by Verhoeven et al. [38].Measurement of protein activities
GAMT activity was determined in lymphoblasts by
assaying the transfer of methyl groups from [2H3]-S-
adenosylmethionine to 13C2-labelled GAA through the
production of [13C2-
2H3]-creatine quantitated by an
isotope dilution electrospray tandem spectrometry
assay [39].
Creatine transporter activity was assayed by determin-
ing the intracellular incorporation of creatine in cultured
skin fibroblasts as previously described [32].Genetic studies
Genomic DNA was isolated from white blood cells or
cultured fibroblasts collected from patients after
informed consent. The coding regions and adjacent in-
tronic splice sites of the GAMT and SLC6A8 genes
were analyzed by direct sequencing. The pathogenicity
of previously non-described mutations was predicted
using the Alamut v2.02 software (Interactive Biosoft-
ware, Rouen France) and compared to the LOVD data-
base [40].Results
Results of the screening for PCD in the French patients
with unexplained neurological symptoms
Among the 6,353 patients screened, 16 patients were
diagnosed to have PCD: 6 with GAMT deficiency (4
male and 2 female patients) and 10 with SLC6A8 defi-
ciency (9 male and 1 female patients). Three additional
affected sibs were identified after familial inquiries (1
brother affected with GAMT deficiency and 2 brothers
with SLC6A8 deficiency in two different families). Diag-
nosis was confirmed by genetic analysis in 17 patients.
For the other 2 patients (1 with GAMT deficiency and 1
with SLC6A8 deficiency), DNA analysis was rejected by
the parents and the diagnosis was confirmed by the ab-
sence of a creatine peak in brain 1H-MRS, the urinary
profile and the deficiency of protein activities. No
patients with AGAT deficiency were identified in our co-
hort. The medical investigations leading to the diagnosis
of these pathologies were requested by pediatric neurol-
ogists (42%), geneticists (32%), pediatricians (10.5%),
adult neurologists (10.5%) and child psychiatrists (5%).
Clinical descriptions and the results of the diagnostic
explorations performed for the index patients and for
the affected sibs are summarized in Table 1. The global
prevalence of PCD in the screened population was
0.25% (16/6,353; CI95: 0.13% - 0.38%), the prevalence of
GAMT deficiency was 0.09% (6/6,353; CI95: 0.02% -
0.17%) and the prevalence of SLC6A8 deficiency was
0.16% (12/6,353; CI95: 0.06% - 0.26%). Regarding our
data, the prevalence of AGAT deficiency would be lower
than 1/6,353, i.e. < 0.02% since no AGAT patient was
diagnosed in the present study. The prevalence of PCD
was 0.29% for the male patients (4 GAMT and 9
SLC6A8 deficiencies, 13/4,426; CI95: 0.14% - 0.46%) and
0.16% for the female patients (2 GAMT and 1 SLC6A8
deficiencies, 3/1,927; CI95: 0.0% - 0.34%). For the X-
linked disorder SLC6A8 deficiency, the prevalence was
0.20% for the male patients (9/4,426; CI95: 0.08% -
0.34%) and 0.05% (1/1,927; CI95: 0.0% - 0.16%) for the
female patients.
Patients with GAMT deficiency
Seven patients from 6 unrelated families were diagnosed
with GAMT deficiency. The sex ratio (M/F) was 2.5.
Five of the 7 patients were born of a consanguineous
union. Most of the patients were of Caucasian origin.
Obstetrical history was available for 5 of the 7 patients;
pregnancies were normal without pre-term birth. The
mean ± SD values for birth-related parameters were:
gestational term, 39.1 ± 0.5 weeks; birth weight, 3192 ±
135 g; birth length, 49.4 ± 1.4 cm and head circumfer-
ence, 34.0 ± 1.2 cm. The predominant clinical signs at
diagnosis were intellectual disability (100%) and speech
delay (100%) (for general information on speech
Table 1 Main clinical, biological, genetic and 1H-MRS
features of the patients affected with PCD
GAMT (n = 7) CRTR (n = 12)
CLINICAL DATA
Sex
Male 5/7 11/12
Female 2/7 1/12
Ratio (M/F) 2.5 11
Consanguinity +++ -
Age of onset (years)
≤ 2 years 6/7 12/12
> 2 years 1/7 0/12
Age at diagnosis(years)
≤ 2 years 1/7 0/12
[2–5 years] 3/7 3/12
[5–10 years] 0/7 4/12
> 10 years 3/7 5/12
Main clinical signs
Intellectual disability ++++ ++++
Speech delay ++++ +++
Failure to thrive + +
Hypotonia ++ +
Myopathy + -
Motor delay ++ +++
Epilepsy ++ +
Extrapyramidal signs + -
Attention deficit ++++ +++
Sleeping disturbances ++ +
Agressive behaviour +++ -
Autistic behaviour ++ +
Signs leading to consult
Combined motor
and speech delay
+++ +++
Epilepsy ++ +
Intellectual disability + -
Autistic behavior - ++
Familial exploration + +
METABOLIC DATA
Plasma GAA (μmol/l)
< 15 years: [0.35-1.8]a [14–23] [0.8 - 2.5]
> 15 years: [1.0-3.5] a [20-23] 2.9
Plasma creatine (μmol/l)
< 10 years: [17–109]a [3.3 - 10] 59; 65
> 10 years: [6.0-50]a [4–6] 100; 112
Urine GAA/creatinine (mmol/mol)
< 15 years: [2–220]a [399–1319] [30–219]
> 15 years: [3–78]a 242; 558 37; 38
Table 1 Main clinical, biological, genetic and 1H-MRS
features of the patients affected with PCD (Continued)
Urine creatine/creatinine (mmol/mol)
< 4 years: [6–1208]a 11; 33 2762
4–12 years: [17–721]a 18; 26 [1638–3015]
> 12 years: [11–244]a [12–32] [1181–3195]
Brain 1H-MRS
investigation
Absence of creatine
peak (n = 5)
Absence of creatine
peak (n = 6)
GENETIC DATA
Non-sense mutation 2/6 0/11
Missense mutation 1/6 2/11
Insertion 0/6 0/11
Deletion 0/6 6/11
Duplication 2/6 0/11
Splicing mutation 1/6 3/11
FUNCTIONNAL TESTS
GAMT Activity
(lymphoblasts)
Deficiency (2/2) /
Creatine transport
assay (fibroblasts)
/ Deficit of
transport (3/3)
This table groups data from the diagnosed PCD patients and affected siblings.
Fraction numbers refer to the number of positive patients (numerator) on the
total number of patients studied (denominator) for the indicated item.
Frequencies of signs in patients are expressed as + and – symbols: ++++,
presence of signs in all patients; -, absence of signs in all patients; +++, ++
and +, presence of the sign in more than 75%, between 25 to 75%, and less
than 25% of patients, respectively. a Reference laboratory values and age
ranges are those published by Verhoeven et al. [38], patient data being
expressed as either range or individual values. GAMT, guanidinoacetate
methyltransferase; CRTR, creatine transporter SLC6A8.
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were associated with epilepsy (57%), motor delay (43%),
hypotonia (43%) and extrapyramidal symptoms (29%).
Behavioral disturbances were noticed in all patients es-
sentially under the form of attention deficit (100%) with
aggressive behaviors (hetero- and/or auto-mutilating epi-
sodes, anger and intolerance to frustration) (86%), autis-
tic behavior (43%) and sleeping disturbances (43%).
Most of these signs were usually present before 2 years
of age and signs leading to consult are detailed in
Table 1.
Diagnosis of GAMT deficiency was established at a
median patient age of 5 years, with age values ranging
between 2 and 29 years. In urine, the GAA:creatinine
ratio (U-GAA/CTN) was increased for all patients and
exceeded the upper control limits by 1.8- to 7.2-fold
whereas the creatine:creatinine ratio (U-CT/CTN) was
normal. When assayed, plasma GAA levels were system-
atically increased and creatine levels were below or equal
to the lowest values of control limits. Cerebral 1H-MRS
was performed in 5 patients and showed that creatine
was undetectable in the brain in all the cases. In 2 of the
7 patients, GAMT activity was measured in lympho-
blasts and these enzyme studies validated GAMT
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patients. In each case, patients had presumed (parents
not available for study) or confirmed (parents were het-
erozygous for the mutation) homozygous mutations
(Table 2). Mutations were either missense (n = 1), non-
sense (n = 2), frame shift (n = 2) or splicing (n = 1)
mutations.
Patients with SLC6A8 deficiency
Twelve patients from 10 unrelated families were identi-
fied with SLC6A8 deficiency. The sex ratio (M/F) was
11. When available, the notion of consanguinity was ab-
sent. Obstetrical history was available for one patient
with a gestational term at 39 weeks; birth weight, 3080
g; length, 48 cm, head circumference, 32 cm. At diagno-
sis, intellectual disability (100%) associated with language
(75%) or motor (83%) delays were reported in most of
the patients. Behavioral abnormalities were observed in
83% (10/12) patients and evoked those seen in GAMT
deficiency patients, notably attention deficit (83%, 10/12
patients) with hyperactivity, autistic behavior (17%) and
sleeping disturbances (8%). No aggressive behavior was
observed. Epilepsy was reported in 17% of the patients.
The main signs leading parents to consult (see Table 1
for an overview) were combined motor and speech
delays; autistic behavior was the second cause of consult-
ation. Familial inquiries led to the diagnosis of SLC6A8
deficiency in 2 of the 12 patients having an affected sib-
ling. Anamnesis indicated that the initial signs could be
present before the age of 2 years with in particular global
psychomotor retardation and to a lesser extent epilepsy
and autistic behavior. The median age for diagnosis was
9.5 years with age values ranging between 2.5 and 28
years.
The U-CT/CTN ratio was increased in all male
patients, and exceeded the upper control limit by 2.3- to
13.6-fold. For the affected girl, the U-CT/CTN ratio was
only 2.3-fold greater than the upper control limit. In
plasma, creatine levels were normal or moderately
increased (up to 1.3-fold greater than the upper control
limit value). Plasma GAA levels were normal (or slightly
affected), as were urinary U-GAA/CTN ratios. CerebralTable 2 Mutations in the GAMT gene
Mutations Number o
Exon (e)/Intron (i) Nucleotide Amino acid Homozy
e2 c.289C > T p.Q97X 1
e2 c.299_311dup13 p.R105GfsX26 2a
i3 c.391 + 15G > T p.(?) 1
e5 c.506G > A p.C169Y 1
e6 c.577C > T p.Q193X 1
Nucleotide numbering starting at the first adenine of the translation initiation codo
a Two affected siblings.1H-MRS was performed in 50% (6/12) of the patients
and consistently confirmed creatine deficiency in the
brain in all examined patients (undetectable creatine
peak). In 3 of the 12 (25%) patients, a functional study
of SCL6A8 activity was carried out in cultured skin
fibroblasts, and evidenced a deficiency of the creatine
transporter function.
The SCL6A8 gene was studied in 92% (11/12) of the
patients (Table 3). A hemizygous mutation was identified
for all the affected male patients. For the female patient,
a pathogenic mutation was identified at a heterozygous
state and no X-inactivation biases could be identified in
leucocytes. Mutations were either missense (n = 2),
frame shift (n = 6) or splicing (n = 3) mutations. The
underlying mutations were also detected in the mothers
of the patients, except for the heterozygous female pa-
tient (c.942_944delCTT in exon 6) and a hemizygous
boy (c.1208C > A in exon 8). In the latter two patients,
SLC6A8 deficiencies were concluded to result from neo-
mutation, germinal or somatic mosaicism.
Discussion
In the present study we have identified 16 new patients
diagnosed with a PCD over a period of 28 months, as
well as three affected siblings. Intellectual disability and
attention deficit were, along with motor and speech
delays, the main symptoms reported by the medical staff
involved in the diagnosis of these disorders. Neverthe-
less, it is surprising that intellectual disability, which was
a sign observed by the medical examiners in all patients
with PCD, was not the main cause leading the parents to
consult. This might reflect the difficulty of identifying in-
tellectual disability in the very young child or in turn to
of associating intellectual disability with PCD. These dis-
orders are known to progress via irreversible lesions of
the brain, so therapeutic measures are needed to be
taken early in the life of the patients. For GAMT
patients, supplementation with creatine together with a
GAA lowering strategy (ornithine supplementation with
or without arginine restriction) may represent an effi-
cient treatment strategy [43-46] and may provide some
medical neurological benefit for GAMT patients. Inf patients identified in this study Reference
gous Heterozygous
- This study
- Dhar et al., 2009 [27]
- This study
- Caldeira Araujo et al., 2005 [63]
- This study
n ATG.
Table 3 Mutations in the SLC6A8 gene
Mutations Number of patients identified in this study Reference
Exon (e)/Intron (i) Nucleotide Amino acid Male Female
Hemizigous Heterozygous
e2 c.321_323delCTT p.F107del 2 a - Degrauw et al., 2002[64]
i4 c.778-2A > G p.(?) 1 - Betsalel et al., 2011[61]
e6 c.926C > A p.A309E 1 - This study
e6 c.930delG p.T311PfsX85 1 - This study
e6 c.942_944delCTT p.F314del - 1 Fons et al., 2009[65]
e6 c.1006_1008delAAC p.N336del 1 - Clark et al., 2006[56]
e8 c.1208C > A p.A403D 1 - This study
i9 c.1393-1G > A p.(?) 2 a - This study
e11 c.1519_1543del p.I507LfsX5 1 - Betsalel et al., 2011[61]
Nucleotide numbering starting at the first adenine of the translation initiation codon ATG.
a Two affected brothers.
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creatine peak as detected by 1H-MRS as well as normal
urine GAA levels. They also improve clinically with bet-
ter language and social development and apparently
some regression of the epilepsy [47]. By contrast, in
patients with SLC6A8 deficiency, supplementations with
creatine and its precursors arginine or glycine, though
improving muscular signs, were found to be without
substantial benefit on cognitive and psychiatric signs,
and failed to modify the creatine signal in 1H-MRS im-
aging of the brain [48], suggesting the inefficacy of these
supplementations in improving brain as stated by other
studies [4,19,30,49-52]. Though there is hope to treat ef-
ficiently this group of patients through the discovery of
creatine pro-drugs capable of entering the brain and
cells via a by-pass of the SCL6A8 creatine transporter,
some clinical studies also question the inefficacy of the
therapeutic measures mentioned above and, on the
contrary, show beneficial effects with creatine and/or ar-
ginine supplementations in patients with SLC6A8 defi-
ciency. In a heterozygous female patient with intractable
epilepsy, treatment with creatine combined with arginine
and glycine completely resolved seizures [53]. Creatine
supplementation was also described to improve the
neurological, language and behavioral status and was
associated with a rise in the brain creatine peak as
demonstrated by MRS in a child with SLC6A8 deficiency
[54]. In a recent study, creatine deficient patients were
also shown to be improved by a L-arginine-based ther-
apy which positively impacted daily living skills, lowered
the frequency of epileptic episodes and induced a mild
increase in brain creatine and phosphocreatine MRS sig-
nals although normal cerebral levels of these metabolites
were not recovered [55].
The calculated prevalence of PCD in our cohort was
0.25%. This result was not expected because moststudies report a higher prevalence of PCD, notably
SLC6A8 deficiency, which is generally estimated be-
tween 1% and 3% of the population affected with intel-
lectual disability [56-59]. However, this prevalence has
been considered to be an overestimation of the real
prevalence of PCD. Because PCDs are monogenic disor-
ders, their prevalence was proposed to be no different
from that of other nonsyndromic diseases such ARX
(Aristaless-Related homeobox gene located on X
chromosome) and therefore closer to 0.1% - 0.3% [60].
Thus, for the first time, our screening study provides
strong practice-based evidence confirming this estimated
prevalence for PCD. The girl diagnosed with SLC6A8
deficiency presented a severe phenotype similar to
affected male patients, an observation that is not sur-
prising in view of recent work [34,61,62] also describing
this X-linked disorder in the female population with in-
tellectual disability. In this respect, screening for
SLC6A8 deficiency in female patients should be included
in the diagnostic workup since this disorder still remains
under-diagnosed. However, it should be noted that if the
urinary U-CT/CTN ratio is not increased the diagnosis
cannot be ruled out because it has been shown that the
majority of female patients with a heterozygous muta-
tion in SLC6A8 have a normal ratio, although the aver-
age ratio of this group is increased [62]. It might be
recommended to perform brain MRS and/or SLC6A8
gene studies in female patients with suspected creatine
transporter deficiency.
Five mutations were identified for GAMT gene in 6
unrelated families. These included 3 new mutations,
c.289C > T, c.391 + 15G > T and c.577C > T, and two pre-
viously described mutations, c.299_311dup13 [27] and
c.506G > A [63] (Table 2). The new mutation c391 +
15G > T was considered pathogenic by the creation of an
alternative splicing donor site in intron 3 (Alamut
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ents and because it was linked with decreased GAMT
activity in cultured fibroblasts.
The SLC6A8 gene was analyzed in 11 patients from 9
unrelated families. Nine mutations were identified
throughout the gene, including 4 new mutations (2 mis-
sense (c.1208C > A and c.926C > A), 1 frameshift
(c.930delG) and 1 splicing (c.1393-1G > A) mutation),
and 5 previously described mutations (c.321_323delCTT
[64], c.942_944delCTT [65], c.1006_1008delAAC [56],
c.778-2A > G and c.1519_1543del [61]) (Table 3). In ac-
cordance with the results of Clark et al. [56], we
found a fairly high proportion of frameshift and spli-
cing mutations in our patients, and approximately one
fifth of the mutations of SLC6A8, but not GAMT, were
attributed to neo-mutation, germinal or somatic mosai-
cism events.
Interestingly, DNA studies performed in our patients
clearly showed that mutations were essentially patient/
family specific and highlighted the absence of hot spot
mutations in these genes. Finally, as a mutation was
identified in each patient for whom DNA was ana-
lyzed, the study of the target gene appears to be a
key diagnostic step for PCD in suspect patients, keep-
ing in mind that secondary creatine disorders such
as deficiencies of ornithine delta-aminotransferase
(EC 2.6.1.13) [66,67], urea [68-71] and homocysteine/
methionine [72,73] cycles, and succinate semialdehyde
dehydrogenase (SSADH) (EC 1.2.1.24) [74,75] may also
be alternative causes of abnormal laboratory values of
creatine metabolism markers.Conclusion
Screening for PCD in the population with neurological
disorders of unknown etiology has shown that these
patients express important clinical signs of PCD which
mainly include intellectual disability, speech delay, epi-
lepsy, attention deficit and autistic behavior.
In this respect, some improvement might be made
by conducting an information campaign among general
and specialized educational staff to contribute to better
recognizing intellectual disability and hence earlier re-
ferral of the child for professional medical evaluation.
Improved anamnesis in regard to the familial history
of possible patients might be also helpful. As suggested
in the present study and highlighted in other work,
both female and male patients can be concerned by
severe PCD. However, and importantly, our study has
shown that the prevalence of PCD remains low in the
patients with unexplained neurological symptoms. Fi-
nally, the mutational spectrum of PCD has been
extended by the new mutations detected during the
present screening effort.Consent
When PCD was suspected informed consent was
obtained from patients and/or their parents for the DNA
analysis of GAMT or SLC6A8 genes.
Additional file
Additional file 1: Updated view of creatine metabolism and
transport. Two enzymes are involved in the biosynthesis of creatine:
arginine-glycineamidinotransferase (AGAT) and
guanidinoacetatemethyltransferase (GAMT). A third protein, a plasma
membrane transporter (SLC6A8), supplies the cell with creatine. A
deficiency of any of these three biosynthesis and transport steps (namely,
AGAT deficiency, GAMT deficiency and creatine transporter deficiency)
leads to a deficiency of creatine in the brain (collapse of brain content in
creatine). Biosynthesis of creatine happens in organs that contain both
AGAT and GAMT. However, particularly in the brain, AGAT and GAMT
may be distributed in different cells, so the guanidinoacetate (GAA)
formed in one cell can be further transformed into creatine in another
cell. This requires, as illustrated in the figure, the creatine transporter
which can supply cells not only with creatine but also with GAA. The
reason for collapse in brain creatine in either AGAT or GAMT deficiency is
easily understood by a severe impairment of one of the two creatine
biosynthesis steps. In creatine transporter deficiency, several facts concur
including : (i) heterogeneity of brain cells for their content in AGAT and
GAMT, (ii) most cerebral cells contain only of one of these two creatine
biosynthesis enzymes; (iii) the blood–brain barrier is weakly permeable to
systemic creatine and the brain must secure most of its creatine
requirements by endogenous synthesis; and (iv) the creatine transporter
contributes in the brain not only to supplying the cells with creatine but
also directly to creatine biosynthesis by bridging the formation of an
intermediate (GAA) in one cerebral cell to its utilization (towards creatine
synthesis) in another cerebral cell. Another protein, the taurine
transporter has also been shown to be active on GAA but in this case it
leads to its removal from brain structures and CSF into blood, a feature
having GAA detoxifying properties, notably in GAMT deficiency. Also
depicted in the figure is the creatine kinase (CK) system (based on
phosphocreatine as a stored form of energy produced from and capable
of restoring ATP) and the non-enzymatic formation from creatine and
phosphocreatine of creatinine (an end product of creatine metabolism
removed in body fluids). Not depicted in the figure is the transit via body
fluids which may take place in intercellular transfer and removal of
creatine metabolites. For additional considerations and references, the
reader is kindly referred to the recent review of Olivier Braissant (Ref [14]
in the text).
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